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Abstract
Type 2 diabetes mellitus (T2DM) is a disorder characterized by both insulin resistance and impaired insulin secretion. Recent
transcriptomics studies related to T2DM have revealed changes in expression of a large number of metabolic genes in a
variety of tissues. Identification of the molecular mechanisms underlying these transcriptional changes and their impact on
the cellular metabolic phenotype is a challenging task due to the complexity of transcriptional regulation and the highly
interconnected nature of the metabolic network. In this study we integrate skeletal muscle gene expression datasets with
human metabolic network reconstructions to identify key metabolic regulatory features of T2DM. These features include
reporter metabolites—metabolites with significant collective transcriptional response in the associated enzyme-coding
genes, and transcription factors with significant enrichment of binding sites in the promoter regions of these genes. In
addition to metabolites from TCA cycle, oxidative phosphorylation, and lipid metabolism (known to be associated with
T2DM), we identified several reporter metabolites representing novel biomarker candidates. For example, the highly
connected metabolites NAD+/NADH and ATP/ADP were also identified as reporter metabolites that are potentially
contributing to the widespread gene expression changes observed in T2DM. An algorithm based on the analysis of the
promoter regions of the genes associated with reporter metabolites revealed a transcription factor regulatory network
connecting several parts of metabolism. The identified transcription factors include members of the CREB, NRF1 and PPAR
family, among others, and represent regulatory targets for further experimental analysis. Overall, our results provide a
holistic picture of key metabolic and regulatory nodes potentially involved in the pathogenesis of T2DM.
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Introduction
Type 2 diabetes mellitus (T2DM) is emerging as one of the main
threats to human health in the 21st century with an estimated 300
million individuals with T2DM by the year 2025 [1,2]. T2DM is
characterized by both insulin resistance (as manifested by reduced
insulin-stimulated glucose uptake in skeletal muscle and adipose
tissue and inappropriately high hepatic glucose output [3,4]) and
reduced insulin secretion by pancreatic b-cells [3,5]. Although the
specific molecular pathophysiology remains unclear, many risk
factors have been identified for T2DM, including family history of
diabetes and prominent environmental factors such as alterations
in early life development, excessive food intake, obesity, decreased
physical activity and aging [2,3,5]. At the cellular level, multiple
regulatory mechanisms and metabolic pathways may contribute to
the pathogenesis of insulin resistance, potentially mediated by
alterations in insulin signaling [6], mitochondrial oxidative
metabolism and ATP production [7–9], fatty acid oxidation
[10], or proinflammatory signaling [11]. Similarly, alterations in b-
cell development and metabolism [5] may contribute to decreased
insulin secretion.
Available human tissue transcriptome data related to T2DM
[12,13] provide an opportunity for identification of novel molecular
mechanisms underlying the metabolic phenotype of T2DM. This
task is challenging due to the need to account for the inherent high
connectivity of bio-molecular interaction networks. We have
utilized a network-centered methodology to link diabetes-related
alterations in gene expression to metabolic hot spots and
transcription factors potentially responsible for gene expression
changes.
Rationale and methodology
Metabolic phenotypes at a cellular level are essentially charac-
terized by concentrations of metabolites and fluxes through the
reactions that make up the metabolic network. Fluxes, in turn, are
dependent on metabolite levels, enzyme activities, abundance of
effectors and possibly other variables. Measurement of fluxes and
metabolite concentrations at the entire metabolic network-scale is,
however, a difficult task in humans due to a variety of technological
and experimental limitations. By contrast, methods for measure-
ment of expression of genes encoding metabolic enzymes are
relatively well-established. Thus, the primary goal of this study is to
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use informatics approaches to integrate available gene expression
data with metabolic networks, in order to predict metabolic
phenotypes of skeletal muscle linked to the pathogenesis of type 2
diabetes. Such an approach will help not only to gain insight into the
organization of transcriptional regulation in human tissues, but also
provide guidance for improved design of experimental strategies for
obtaining metabolite and flux data, which can be further integrated
into metabolic models.
To achieve these goals, we applied an extension of the algorithm
described in [14] (for various applications of this algorithm see
[14–18]), which enables identification of so-called reporter
metabolites, or metabolic hot spots around which transcriptional
regulation is centered (Figure 1A). This analysis is based on the
assumption that under most conditions of physiological interest,
fluxes through enzymes connected to a metabolite are coordinated
in order to maintain physiological homeostasis, or to eventually
reach a new (pseudo-) steady state. Moreover, transcriptional
regulation of expression of genes encoding critical enzymes in
metabolic flux pathways facilitates concordance with the metabolic
demands of the cell and corresponding stoichiometric and
thermodynamic constraints on fluxes. For this analysis, we used
two recently published human metabolic network models: i) Homo
sapiens Recon1 [19], and ii) Edinburgh Human Metabolic Network
(EHMN) [20].
We further hypothesized that the observed coordinated changes
around reporter metabolites can be, at least in some cases,
attributed to common transcriptional regulatory mechanisms.
Specifically, we hypothesize that the neighbor enzymes of reporter
metabolites may share one or more transcription factor binding
sites in the promoter regions of the corresponding genes. In order
to identify such potential regulatory players, we tested promoter
sequences of the genes associated with the reporter metabolites for
enrichment of known transcription factor binding motifs
(Figure 1B). Transcription factors identified in this fashion provide
Author Summary
Type 2 diabetes mellitus is a complex metabolic disease
recognized as one of the main threats to human health in
the 21st century. Recent studies of gene expression levels
in human tissue samples have indicated that multiple
metabolic pathways are dysregulated in diabetes and in
individuals at risk for diabetes; which of these are primary,
or central to disease pathogenesis, remains a key question.
Cellular metabolic networks are highly interconnected and
often tightly regulated; any perturbations at a single node
can thus rapidly diffuse to the rest of the network. Such
complexity presents a considerable challenge in pinpoint-
ing key molecular mechanisms and biomarkers associated
with insulin resistance and type 2 diabetes. In this study,
we address this problem by using a methodology that
integrates gene expression data with the human cellular
metabolic network. We demonstrate our approach by
analyzing gene expression patterns in skeletal muscle. The
analysis identified transcription factors and metabolites
that represent potential targets for therapeutic agents and
future clinical diagnostics for type 2 diabetes and impaired
glucose metabolism. In a broader perspective, the study
provides a framework for analysis of gene expression
datasets from complex diseases in the context of changes
in cellular metabolism.
Figure 1. Schematic overview of the methodology used for the identification of reporter metabolites and associated putative
regulatory sequence motifs. A) Scoring system for identification of reporter metabolites. Each metabolite is scored based on the scores of the
associated enzyme-catalyzed reactions. Each enzyme, in turn, is assigned a score based on median of the p-values of the probes representing the
corresponding gene. In case of a reaction catalyzed by an enzyme complex or a set of isozymes, minimum of the p-values of the corresponding
enzymes is chosen. Numbers in bold are Z-scores for each reaction, the rest of the numbers represent p-values (significance of differential
expression). B) Identification of transcription factor binding motifs. For a reporter metabolite, a set of up/down regulated neighbor (enzyme-coding)
genes is selected. Promoter regions, upstream of transcription start site (TSS) of each of the selected genes are assessed for the enrichment of known
transcription factor (TF) binding sequence motifs.
doi:10.1371/journal.pcbi.1000729.g001
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clues to the regulatory mechanisms that lead to observed gene
expression changes in the metabolic network.
Since our goal is to identify reporter metabolites and
transcription factors potentially involved in diabetes pathogenesis
and progression, we analyzed two independent studies of skeletal
muscle transcriptomics in individuals with established type 2
diabetes or insulin resistance [8,9] (Text S1). In the first study [8],
biopsies were obtained following insulin stimulation from a cohort
of 43 Swedish men of Caucasian ethnicity with a spectrum of
glucose tolerance, including 17 with normal glucose tolerance
(NGT), 8 with impaired glucose tolerance (IGT), and 18 with
established T2DM. The second dataset [9] was derived from a
cohort of 15 subjects of Mexican American ethnicity, in whom
muscle biopsies were performed in the fasting state. Importantly,
this cohort included individuals with not only established diabetes
(5 subjects, T2DM), but also individuals with completely normal
glucose tolerance but a spectrum of insulin resistance; normal
glucose tolerant subjects were subdivided by family history-linked
diabetes risk (4 family history positive, more insulin resistant
subjects, FH+; and 6 family history negative, more insulin sensitive
subjects, FH2). With this approach, the individual contributions
of isolated insulin resistance and diabetes risk (in the setting of
normoglycemia, FH+), mild elevations in postprandial glucose
(IGT), and established diabetes can be individually assessed.
Moreover, the possible contribution of family history, potentially
mediated by genetics or shared environment, can be assessed.
Thus, we predict that analysis of the common patterns resulting
from the two datasets will identify regulatory signatures potentially
independent of study cohort and design variation but common to
the pathophysiology of insulin resistance and diabetes.
Results
In present study, we performed reporter metabolite analysis
based on pair-wise comparisons within each dataset; differential
expression and its significance were assessed with robust multi-
array average (RMA) and empirical Bayes testing. Significance of
differential expression for each gene was used as a scoring metric
(Materials and Methods). The results are summarized as metabolic
signatures (reporter metabolites) and regulatory signatures (tran-
scription factors) for T2DM.
Metabolic signatures of T2DM
Swedishmale dataset. Reporter metabolite analysis for three
pair-wise comparisons, viz., T2DM vs NGT, T2DM vs IGT, and
IGT vs NGT, revealed significant reporter metabolites (p-
value#0.05) participating in lipid metabolism, TCA cycle,
oxidative phosphorylation (OXPHOS) and glycolysis (Table 1,
Table 2, Table S1 and Table S2). Among reporter metabolites
identified for the T2DM vsNGT comparison were lipid species 1,2-
diacyl-sn-glycerol (DAG), acetoacetyl-CoA, and the sphingolipid
sphinganine. These are interesting, as prior studies [3,21–23] have
demonstrated that the related lipid molecules diacylglycerols
(DAG), long-chain fatty acyl CoAs, and ceramides correlate
positively with triglyceride content and inversely with insulin
sensitivity [5] and have been shown to induce insulin resistance
[3]. Furthermore, given that saturated fatty acids appear to play a
particularly important pathogenic role in insulin resistance [24], it is
interesting that several metabolites of saturated fatty acids (such as
hexanoyl-CoA, palmitoyl-CoA, tetradecanoyl-CoA, lauroyl-CoA,
decanoyl-CoA and butanoyl-CoA) were found as reporter
metabolites with mostly up-regulated neighboring genes in the
IGT vs NGT comparison (Table 1 and S2), and thus may serve as
potential markers of insulin resistance and IGT.
TCA cycle metabolites citrate and 2-oxoglutarate, with down-
regulated neighboring genes, were also uncovered as reporter
metabolites in the T2DM vsNGT comparison (Table 1, S1 and S2).
These results are concordant with a study of human urine
metabolome profiles from patients with T2DM [25], in which
levels of citrate and 2-oxoglutarate were lower in T2DM compared
to healthy controls [26]. Among other mitochondrial metabolites,
reduced and oxidized forms of cytochrome c and ubiquinol were
identified as reporter metabolites (T2DM vs NGT, Table S1) with
down-regulated expression of the associated genes.
Impaired glucose tolerance typically reflects an important
transition between normoglycemia and overt diabetes, reporter
metabolites which are identified in both IGT vs NGT and T2DM
vs NGT, but not significantly different in the T2DM vs IGT
comparison (e.g. phosphatidylethanolamine, 2-hydroxyglutarate,
2-oxoglutarate, 39,59-cyclic AMP, ATP, Table S1 and S2) may be
considered novel biomarkers of early-stage glucose intolerance.
Mexican-American dataset. We similarly performed reporter
metabolite analysis using both Recon1 and EHMNmetabolic models
in the Mexican-American dataset. This analysis revealed significant
transcriptional regulation in metabolite nodes in TCA cycle,
oxidative phosphorylation, and lipid metabolism, for both T2DM
vs FH2 and FH+ vs FH2 comparisons (Table 2). Similar to the
Swedish Caucasian dataset, metabolites involved in oxidative
phosphorylation (e.g. ferrocytochrome c, H+, and fumarate) were
among the top-ranking reporter metabolites, identified in both the
T2DM vs FH2 and FH+ vs FH2 comparisons (Table 2, Table S3).
Interestingly, urinary levels of fumarate, an important link between
the TCA cycle and oxidative phosphorylation, were recently found to
be decreased in T2DM patients [25].
Analysis using the EHMN model revealed TCA cycle-related
metabolites, including 3-carboxy-1-hydroxypropyl-ThPP, aconi-
tate, succinyl-CoA, malate and fumarate, as significant reporter
metabolites (p-value#0.05), with mostly down-regulated expres-
sion of the genes encoding their neighboring enzymes. Ubiquinol
was found as reporter metabolite representative of electron
transfer chain. Several molecules within b-oxidation pathways,
such as 3-cis-dodecenoyl-CoA, glutaryl-CoA, trans-3-decenoyl-
CoA, 3-methylbutanoyl-CoA and 3-methylcrotonyl-CoA, as well
as in amino acid (leucine, lysine) metabolism were also identified as
reporters (Table 2, Table S4). Moreover, glutamate, glycerol
derivatives, phosphocreatine, a number of hormone derivatives
and many others (Table S3 and S4) were found as significant
reporter metabolites in the T2DM vs FH2 comparison.
Overlapping reporter metabolites between two study
populations. In order to determine the extent of overlap
between the two study populations, we performed a cluster
analysis of the pair-wise comparisons within the Swedish and
Mexican-American datasets (Figure 2). Jaccard distance metric
between two pair-wise comparisons (e.g. T2DM vs FH2 and FH+
vs FH2) was calculated based on the overlap of reporter metabolites
between the two comparisons. Jaccard distance provides a measure
of dissimilarity between two sets of reporter metabolites, and is
quantified as the fraction of non-overlapping reporter metabolites
between the two sets. While similar clustering patterns were
observed (Figure 2A and Figure S1A) independent of the use of
either EHMN or Recon1 metabolic model, Swedish and Mexican-
American studies clustered separately, perhaps related to differences
in study population, study design (e.g. fasting studies in Mexican-
Americans, insulin-stimulated studies in Swedish) or differences in
microarrays used (thus differing in the coverage of metabolic
enzymes). We observed substantial overlap between the T2DM vs
FH2 and FH+ vs FH2 comparisons, suggesting that insulin
resistance patterns could contribute to these findings.
Metabolic Regulatory Signatures of Type 2 Diabetes
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We next examined the overlap of reporter metabolites between
the two case studies (Figure 2B, Figure S1B, Table S5 and Table
S6). Owing to differences in the metabolite-gene connectivity
between EHMN and Recon1, the number of overlapping reporter
metabolites is generally higher for the EHMN analysis. To a large
extent, this difference is due to the groups of metabolites in
EHMN that share the same gene neighbors (whether two
metabolites share the same gene neighbors depends not only on
the network used, i.e. number of distinct biochemical reactions
associated with a particular enzyme, but also on the coverage of
genes on the particular microarray chip used). In addition to many
other metabolites, phosphocreatine appeared as a significant
Table 1. Reporter metabolites for Swedish male dataset.
Reporter Metabolite P-values
Enzyme neighbors
(Up-regulated:Down-regulated)
T2DM/NGT IGT/NGT T2DM/NGT IGT/NGT
Citrate 0.047 0.646 1:0 1:0 TCA cycle
Succinyl-CoA 0.013 0.285 2:3 2:3
2-Hydroxyglutarate* 0.002 0.023 0:1 0:1
2-Oxoglutarate* 0.049 0.047 8:11 8:11
Ferrocytochrome C; Ferricytochrome C 0.006 0.032 1:2 0:3 Oxidative phosphorylation
Ubiquinone-10 0.017 0.769 0:5 1:4
Ubiquinol-10 0.022 0.484 0:4 1:3
Phosphoenolpyruvate* 0.196 0.037 1:3 1:3 Glycolysis
D-Glyceraldehyde* 0.083 0.017 2:1 3:0
D-Alanine 0.016 0.330 0:3 0:3 Amino acid metabolism
L-Alanine 0.047 0.319 3:7 3:7
3-Methylglutaconyl-CoA{ 0.038 0.816 0:2 1:1
L-Leucine* 0.047 0.109 1:3 1:3
1,2-Diacyl-sn-glycerol (DAG)* 0.022 0.049 2:5 2:5 Lipid metabolism
1D-myo-Inositol 1,4-bisphosphate{ 0.060 0.151 0:3 2:1
3-Dehydrosphinganine* 0.232 0.035 1:1 2:0
Acetoacetyl-CoA* 0.009 0.462 1:4 2:3
Butanoyl-CoA{ 0.365 0.038 0:2 1:1
Decanoyl-CoA; Lauroyl-CoA* 0.268 0.033 1:2 2:1
Fatty acid* 0.021 0.756 3:4 3:4
Lophenol*1 0.007 0.749 0:1 0:1
Palmitoleoyl-CoA* 0.238 0.019 1:3 2:2
Palmitoyl-CoA* 0.179 0.014 3:4 6:1
Phosphatidyl glycerol phosphate 0.047 0.316 0:1 0:1
Phosphatidylinositol 4,5-bisphosphate 0.097 0.001 1:5 2:4
Propanoyl-CoA* 0.259 0.016 2:5 2:5
Prostaglandin E2 0.036 0.032 0:3 1:2
Sphinganine* 0.038 0.283 1:3 2:2
(Gal)3 (GalNAc)1 (Glc)1 (Cer)1* 0.023 0.034 1:2 1:2 Other
AMP{ 0.041 0.218 7:17 6:17
ATP{ 0.003 0.010 28:60 27:60
cAMP{ 0.033 0.049 2:0 2:0
CDPcholine 0.020 0.122 0:2 0:2
Choline phosphate 0.030 0.573 0:2 1:1
NAD+* 0.333 0.020 29:34 34:34
Phosphocreatine 0.025 0.176 0:1 1:0
Trichloroethanol* 0.020 0.038 1:2 3:0
*Reporter metabolites identified using EHMN metabolic network.
{Reporter metabolites identified in both networks.
1Plant metabolite, likely to be present in the EHMN due to incorrect annotation.
Reporter metabolites with p#0.05 in at least one of the comparisons showed in bold. Columns with enzyme neighbors show the number of up- and down-regulated
enzyme neighbors in the first condition (e.g. T2DM/NGT up- and down-regulated in T2DM comparing with NGT) for each of comparisons. Reporter metabolites without
marks were identified using Recon1 metabolic network. Metabolites written in italics are known to be directly/indirectly related to T2DM, see main text and Table S8.
doi:10.1371/journal.pcbi.1000729.t001
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reporter in both case studies, viz., for T2DM vs NGT and T2DM vs
FH2 comparisons. Phosphocreatine is an important energy
reservoir metabolite in skeletal muscle, and defects in recovery of
phosphocreatine have been identified in vivo in humans with insulin
resistance [27] and diabetes [28]. Interestingly, low levels of urinary
creatine have also been found in patients with T2DM [25].
Regulatory signatures of T2DM
In order to link the identified reporter metabolites to regulatory
pathways controlling gene expression, we hypothesized that en-
zymes associated with reporter metabolites would be regulated by
common transcription factors. As potential candidates subjected to
such regulation, we selected all reporter metabolites with at least 5
Table 2. Reporter metabolites for Mexican-American dataset.
Reporter metabolite P-values
Enzyme neighbors
(Up-regulated:Down-regulated)
T2DM/FH2 FH+/FH2 T2DM/FH2 FH+/FH2
2-Oxoglutarate 0.001 0.001 2:7 2:7 TCA cycle
L-Malate 0.098 0.029 1:4 2:3
Succinyl-CoA{ 0.011 0.009 0:5 0:5
Ferrocytochrome C;Ferricytochrome C 0.008 0.007 0:3 0:3 Oxidative phosphorylation
Fumarate 0.019 0.025 0:2 0:2
Ubiquinone-10{;Ubiquinol-10{ 0.040 0.021 1:3 1:3
2,3-Disphospho-D-glycerate{ 0.021 0.004 0:1 0:1 Glycolysis
2-Phospho-D-glycerate* 0.038 0.006 0:2 1:1
beta-D-Fructose* 0.049 0.038 0:2 0:2
D-Fructose 2,6-bisphosphate 0.037 0.136 0:2 0:1
D-Fructose 6-phosphate 0.013 0.119 4:6 3:7
D-Glucose* 0.037 0.066 0:7 1:5
D-Glucose 6-phosphate 0.009 0.014 1:3 1:3
D-Glycerate 2-phosphate 0.026 0.003 0:2 1:1
L-Lactate 0.048 0.067 1:2 1:2
Phosphoenolpyruvate 0.079 0.048 2:2 3:1
Pyruvate 0.042 0.202 1:6 1:6
2-Oxoadipate* 0.002 0.004 0:1 0:1 Amino acid metabolism
beta-Alanine 0.031 0.027 1:1 1:1
L-Glutamate{ 0.025 0.009 1:1 1:1
(R)-2-Methyl-3-oxopropanoyl-CoA* 0.043 0.118 0:2 0:1 Lipid metabolism
1,2-Diacyl-sn-glycerol (DAG)* 0.036 0.117 3:2 5:1
1D-myo-Inositol 1,4-bisphosphate 0.025 0.054 1:2 1:2
3-cis-Dodecenoyl-CoA* 0.009 0.039 0:3 0:3
Acylglycerol*; 2-Acylglycerol* 0.035 0.018 1:1 1:1
Glutaryl-CoA{ 0.007 0.015 0:2 0:2
Glycerol 0.020 0.001 1:1 1:1
Glycerol 3-phosphate 0.051 0.005 2:1 2:1
Lipoamide* 0.014 0.006 0:5 0:5
Phosphatidylinositol 0.017 0.128 1:5 1:5
trans-3-decenoyl-CoA* 0.026 0.076 0:2 0:2
ADP 0.047 0.174 16:31 20:27 Other
CO2 0.041 0.004 1:11 3:9
Coenzyme A{ 0.007 0.014 4:8 3 10
Creatine;Phosphocreatine{ 0.032 0.048 0:1 0:1
NAD+{; NADH{ 0.003 0.095 3:17 17:4
Trichloroethanol* 0.021 0.006 2:1 3:0
*Reporter metabolites identified using EHMN metabolic network.
{Reporter metabolites identified in both networks.
Reporter metabolites with p#0.05 in at least one of the comparisons showed in bold. Columns with enzyme neighbors show the number of up- and down-regulated
enzyme neighbors in the first condition (e.g. T2DM/FH2 up- and down-regulated in T2DM comparing with FH2). Reporter metabolites without marks were identified
using Recon1 metabolic network. Metabolites written in italics are known to be directly/indirectly related to T2DM, see main text and Table S8.
doi:10.1371/journal.pcbi.1000729.t002
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up- or down-regulated neighboring genes (Materials and Methods).
Up- and down-regulated gene sets were then analyzed separately
in order to assess whether their promoter regions were enriched
for known transcription factor binding sequence motifs. P-values
for enrichment were estimated by using a hypergeometric test,
which compared the proportion of promoters from a given gene
set containing a particular motif with the frequency of occurrence
of that motif in promoter regions of all other metabolic genes.
Correction for multiple-testing was done by using q-value [29]
and motifs with q-value#0.05 were considered as significantly
enriched.
In accord with our hypothesis, several transcription factor
binding sites were overrepresented in the promoter regions of the
enzymes associated with reporter metabolites. A summary of the
main results from this analysis is illustrated in Figure 3A. Many
transcription factors were found to be common across the two case
studies (Figure 3B), albeit in connection with different reporter
metabolites. PPAR family motifs (PPARc and PPARa:RXRa)
were enriched in seven downregulated enzyme sets including ATP.
Tax/CREB motifs were enriched in promoters of downregulated
enzymes associated with ATP, ADP and phosphate. Additional
down-regulated neighbors of ATP were enriched for the binding
sites of NF-kB, MEF-2, UF1-H3b, Pax-9 and NKX6.2, while the
NRF-1 motif was enriched in the set of up-regulated enzymes
neighboring ADP. Another potential regulatory signature was
identified around the down-regulated neighbors of phosphatidy-
linositol and phosphatidylinositol 4,5-bisphospate (important
phospholipids which participate in insulin and other signaling
reactions), which were significantly enriched for binding sites of
p53, PPARc, SRF, SEF-1, v-Jun, GCNF, AR and many others
(Table S7). These and other highly connected reporter metabolites
in the metabolite-TF network (Figure 3A) demonstrate the concept
that associated metabolic pathways can be transcriptionally
regulated in multiple ways in response to environmental stimuli
or metabolic perturbation.
Discussion
Maintenance of whole-body glucose metabolism is reliant on a
delicately balanced dynamic interaction between tissue sensitivity to
insulin (including muscle, adipose and liver) and insulin secretion
[5,30]. Unfortunately, the molecular mechanisms responsible for
diabetes risk remain unknown. A key metabolic phenotype
associated with insulin resistance in humans is inappropriate lipid
accumulation in tissues outside of adipose tissue, suggesting defects
in fatty acid uptake, synthesis, and/or oxidation. With lipid excess
and/or impaired oxidation, as observed in obesity and/or inactivity,
flux of long-chain acyl CoAs (LC-CoA) may be redirected into
cytosolic lipid species such as diacylglycerols (DAG), triacylglycerols
(TG) and ceramides (derivatives of sphingosine and fatty acid
metabolism) [5] that are correlated with reductions in insulin
signaling and insulin resistance [3,21–23,31].Whether alterations in
mitochondrial oxidative function in humans with insulin resistance
and diabetes contribute to, or are a consequence of these defects,
remains unclear [32].
Recognizing these important gaps in our knowledge of diabetes
pathophysiology, we have integrated transcriptomic data with
metabolic networks to systematically identify, in an unbiased
fashion, regulatory hot spots (reporter metabolites and associated
transcription factors) associated with insulin resistance and T2DM.
Our reporter metabolite results provide evidence for transcrip-
tional dysregulation of multiple metabolic pathways in skeletal
muscle. Interestingly, many of the reporter metabolites identified
in our analysis have been appreciated in prior experimental studies
in animal models (metabolites with italic font in Tables 1, 2 and
S8). A bird’s-eye view of selected metabolic and regulatory nodes
identified in our study is depicted in Figure 4.
Key metabolic regulatory nodes in T2DM pathogenesis
Lipid metabolism. In conditions of overnutrition and
physical inactivity, availability of cellular fatty acids stimulate
Figure 2. Hierarchical clustering of pair-wise comparisons within the Swedish male and Mexican-American datasets based on the
overlapping reporter metabolites (Recon1 model). Comparisons are colored according to the dataset; blue – Mexican-American; orange –
Swedish male dataset. A) Dendrogram of reporter metabolites identified in each of the comparisons based on Jaccard distance. B) Venn diagram
showing the overlap of the reporter metabolites identified in the different comparisons.
doi:10.1371/journal.pcbi.1000729.g002
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ligand–dependent PPARa/d transcription factors which, in turn,
induce transcription of genes responsible for b-oxidation [33,34].
Metabolic byproducts of incomplete b-oxidation, such as
acylcarnitines and reactive oxygen species, may accumulate in
mitochondria and contribute to insulin resistance [5]. Inter-
estingly, our analysis identified enrichment of PPAR family
transcription factor binding motifs in T2DM as compared with
insulin sensitive subjects, in both the Swedish and Mexican-
American datasets (T2DM vs NGT and T2DM vs FH2, re-
spectively). Moreover, reporter analysis revealed lipid metabolites
(Table S1), known to be natural ligands of PPARc (prostaglandins)
[34].
Another reporter metabolite identified in our analysis is
diacylglycerol (DAG), a lipid signaling molecule known to inversely
correlate with insulin sensitivity [3,21–23,31]. Our results suggest
that perturbations in DAG levels may be accompanied by changes
in the adjacent CDP-Choline branch of the Kennedy pathway of
phospholipid metabolism (Figure 4). Thus, DAG could potentially
affect insulin sensitivity via activation of serine/threonine kinases or
alterations in phospholipid membrane composition, both of which
could lead to defects in insulin signaling, reduced insulin-stimulated
glucose uptake, and glycogen synthesis – key metabolic features of
diabetes [5] (Figure 4). Together, identification of these lipid-linked
regulatory motifs and reporter metabolites known to be involved in
type 2 diabetes pathogenesis provides further support for the validity
of our approach.
Central carbon metabolism. Using our approach we found
several reporter metabolites from the TCA cycle (citrate, 2-
oxoglutarate, succinyl-CoA, fumarate and malate) (Figure 4). The
down-regulated genes associated with these metabolites support
the idea that TCA cycle and/or oxidative phosphorylation flux is
reduced in diabetes [9]. It is also interesting that ATP is one of the
reporter metabolites, as the majority of cellular ATP is generated via
respiration. Moreover, significant enrichment of binding motif for
NF-kb in the upregulated ATP neighbors is consistent with the
potential role of this transcription factor in mediating oxidative
stress responses triggered by by-products of incomplete b-oxidation
[35]. Another interesting finding is the enrichment of CREB family
and NRF-1 motifs in enzymes associated with ATP and ADP.
These results corroborate the role of CREB as an indirect regulator
of nuclear-encoded oxidative phosphorylation genes via PGC1-a
and other regulators linked to nuclear-encoded mitochondrial genes
(Figure 4) [9,36,37].
The appearance of highly connected metabolites, such as ATP
and NADH, among top-ranking reporter metabolites provides a
possible link to the observed network-wide transcriptional changes
in IGT and T2DM. Cellular levels of these co-factors are usually
constrained within relatively narrow ranges to maintain thermo-
dynamic stability. Oxidative phsophorylation, which is connected
to TCA cycle flux via succinate and fumarate, accounts for most of
the ATP (and NADH) turnover in a respiring cell. Our results
suggest reduction in the activity of both TCA cycle and oxidative
phosphorylation, in agreement with recent NMR data demon-
strating that mitochondrial ATP synthesis is reduced in humans
with insulin resistance [38–40]. Another major source of ATP and
NADH production in the cell is glycolysis. Reporter metabolites
representative of glycolysis (glucose, glucose-6-phosphate, glucose-
1-phosphate and pyruvate) also exhibited concordant down-
regulation of the neighboring genes.
The concordance between the changes in gene expression levels
for glycolysis, TCA cycle and oxidative phosphorylation in IGT
and T2DM suggests that transcriptional regulatory mechanisms
Figure 3. Summary of the main results from the motif enrichment analysis. A) Motif enrichment analysis for the genes associated with
reporter metabolites from the T2DM vs NGT comparison. Reporter metabolites with up-regulated neighboring gene set are shown as red circles,
whereas reporter metabolites with down-regulated neighboring gene set are represented as green circles. Transcription factor binding motifs (shown
as triangles) are colored according to the number of enzyme sets in which they are enriched, ranging from light yellow (enriched in few sets) to
orange (enriched in as many as 6 sets). Edges are scaled according to q-values signifying the confidence of the motif enrichment. B) Venn diagram
showing the overlap of transcription factor binding motifs across the comparisons of T2DM with non-T2DM cases. Comparisons are colored
according to the dataset; blue – Mexican-American; orange – Swedish male dataset.
doi:10.1371/journal.pcbi.1000729.g003
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may be a response to altered levels of ATP/NADH. Such response
may achieve two purposes: (1) regulation of metabolism on global
scale, as these co-factors are critical components of many metabolic
pathways, and (2) regulation of NADH levels may help in reducing
excessive (and potentially deleterious) oxidative stress resulting from
sustained oxidation of excessive nutrients [41]. Although the way
such regulatory control is mechanistically linked to the correspond-
ing metabolites cannot be deduced from the gene expression data
alone, there are several examples where metabolite co-factors are
directly involved in regulating gene expression, e.g. NADH(/+)
dependent regulation of genes in gram-positive bacteria [42], yeast
[43–45] and human [46,47]. NAD+ dependent changes in gene
expression levels could also be mediated by the action of PGC-1a
and SIRT1 complex, which have important roles in regulation of
glucose homeostasis [48]. Additional regulatory links, between
glycolytic flux, energy metabolism, TCA cycle flux and fatty acid
metabolism are also known in other eukaryotic systems such as
baker’s yeast [49–51]. Furthermore, several of the enzymes from
central carbon metabolism may be regulated to a large extent at the
post-transcriptional level [52,53]. Parallels of such regulatory
Figure 4. Metabolic and regulatory signatures of type 2 diabetes. Key metabolic and regulatory pathways associated with reporter
metabolites identified in this study (T2DM vs NGT and T2DM vs FH2 comparisons) are shown. Metabolites in bold black font are reporter metabolites.
Grey shapes and arrows represent facts/hypotheses from previous studies and are not directly based on the results from the present study. Broken
lines imply indirect effect while full lines denote direct effect. Chronic overfeeding and physical inactivity increase the influx of fatty acid, which
promotes b-oxidation through the activation of PPARa/d-mediated genes, without coordinated increase in TCA cycle flux. Reporter analysis supports
this idea by showing the decreased activity in TCA cycle enzymes associated with reporter metabolites. Eventually, this leads to mitochondrial
accumulation of metabolic by-products of incomplete b-oxidation (acylcarnitines ROS). These stresses might lead to mitochondrial overload which
together with intracellular lipid-signaling (such as DAG) molecules might trigger serine a serine/threonine (Ser/Thr) kinase (Ser/Thr) cascade initiated
by nPKCs. As a result, Ser/Thr phosphorylation of insulin receptor substrate 1 (IRS-1) sites is induced, thereby inhibiting IRS-1 tyrosine phosphorylation
and activation of PI 3-kinase, resulting in impeded GLUT4 translocation, reduced glucose transpor, and decreased glycogen synthesis. Increased
physical activity/fasting activates PGC1a and CREB (a potent inducer of PGC-1a). These actions combat lipid stress by increasing TCA cycle flux and by
coupling ligand-induced PPARa/d activity with PGC1a-mediated remodeling of downstream metabolic pathways such as respiration and b-oxidation.
CDP-choline, cytidine diphosphate choline; DAG, diacylglycerol; G1P, glucose 1-phosphate; G6P, glucose 6-phosphate; GLUT4, glucose transporter-4;
GSK3, glycogen synthase kinase-3; IRE1, inositol requiring kinase-1; LC-CoAs, long-chain acyl CoAs; nPKCs, novel protein kinase Cs; PA, phosphatidate;
PGC1a, PPARc co-activator-1a; PH, pleckstrin homology domain;PI, phospatidylinositol; PIP, phospatidylinositol 4-phospate; PIP2, phosphatidyli-
nositol 4,5-bisphospate, PIP3, phospatidylinositol 3,4,5-trisphospate; PI 3-kinase, phosphoinositol 3-kinase; PPARc, peroxisome proliferator-activated
receptor-c; PTB, phosphotyrosine binding domain; ROS, reactive oxygen species; RXR, retinoid X receptor; SH2, src homology domain; TCA,
tricarboxylic acid cycle; TF, transcription factor; CPT1, carnitine palmitoyltransferase-1; PTDETN, phosphatidylethanolamine.
doi:10.1371/journal.pcbi.1000729.g004
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circuits in human cells may be discovered in the future with the
here-identified transcription factors (Table S7) as one of the starting
points.
Other pathways. Metabolites involved in protein and lipid
glycosylation were found as reporters and characterized by down-
regulation of neighboring enzymes (Table S2). Alterations in
glycosylation may ultimately cause misfolding of several proteins, a
feature previously associated with over-nutrition in hepatocytes [5].
Another reporter metabolite, shared by T2DM vsNGT and T2DM vs
FH2 comparison, is trichloroethanol, a metabolite in the cytochrome
P450-mediated pathway derived from trichlorethene [54]. Although
tricholoethanol or tricholoethene is not an endogenous metabolite in
human tissues, it appears that the expression of the cytochrome P450
is altered in T2DM. Interestingly, experimental evidence shows that
mouse exposure to trichlorethene leads to PPARa activation and the
reprogramming of gene expression, resulting in induction of enzymes
mediating b- and v-oxidation of fatty acids, and increased expression
of genes involved in lipid metabolism [55], a pattern similar to the
T2DM metabolic phenotype [3].
Reporter metabolites and macroscopic physiological
parameters
The identification of reporter metabolites from glycolysis and
energy-generation pathways suggests that there may be regulation of
certain physiological parameters, such as glucose uptake, at the
transcriptional level of the corresponding metabolic pathways. To
investigate the extent of such possible regulation, we calculated
Pearson correlation coefficients between insulin sensitivity (as
measured by either whole-body glucose uptake during the
hyperinsulinemic euglycemic clamp or insulin levels achieved during
the OGTT) and mean centroid expression levels of genes
surrounding reporter metabolites (Swedish dataset) (Materials and
methods). A significant linear correlation with whole-body glucose
uptake was observed for several reporter metabolites. In most cases,
the correlation was significant only for one of the conditions (NGT,
IGT or T2DM). For example, significant correlation of transcrip-
tional regulation around dUDP with glucose uptake was found only
for NGT samples (Figure 5A). It appears that this potential
connection is de-linked under IGT and T2DM conditions. Another
example is 1-Phosphatidyl-1D-myo-inositol 3-phosphate (Figure 5B),
where significant correlation is observed with insulin level only for
IGT. Further investigation of the causal mechanisms behind these
observed correlation patterns may help in elucidating the regulatory
role of the reporter metabolites in diabetes pathogenesis.
Potential biomarkers and pharmacological targets
A key scientific and clinical challenge is to identify molecular
markers of diabetes risk, not only to better understand disease
pathophysiology, but also to develop novel therapies for
prevention and treatment of established diabetes. In this context,
it is interesting that our analysis identified both PPARc and its
potential lipid ligands as regulatory molecules, since PPARc ligand
thiazolidinediones are currently employed as effective therapy for
diabetes. We hypothesize that some transcriptional pathways
identified in the current analysis, including CREB, NRF-1 and
SRF, may be additional novel molecular mediators of the
transcriptomic phenotype associated with insulin resistance, and
thus potential targets for future intervention strategies. Of course,
the potential roles of these pathways will require additional testing
in cultured cells and animal models, where their impact on
metabolic flux and insulin sensitivity can be fully assessed.
Similarly, reporter metabolites identified in our analysis represent
molecules likely to be involved in human skeletal muscle insulin
resistance phenoytpes and also novel candidate biomarkers of
insulin resistance and diabetes risk. In support of this hypothesis,
several of the identified metabolites have known physiological roles
in T2DM (Table S8 and Discussion above). Additional molecules
have been analyzed either in rodents and/or in other tissues (Table
S8) and thus, their appearance as reporter metabolites also strongly
implicates their involvement in insulin resistance in human skeletal
muscle. Some of the novel metabolites identified in our analysis,
including glycolytic and fatty acid oxidation intermediates, are
known targets of metformin, a compound effective for diabetes
therapy and prevention (Figure 4). We also identified an interesting
link between DAG, a reporter metabolite for T2DM, and the CDP-
choline branch of the Kennedy pathway of phospholipid metabo-
lism (Figure 4). This pathway has been implicated in cancer
development and is being established as anti-tumor drug target
[56,57]. Changes in phospholipid metabolism are known to affect
the properties of cellular membranes, and subsequently signaling
through membrane proteins. Further investigation of the role of
phospholipids in T2DM pathogenesis may provide clues to some of
the missing links that connect metabolic flux changes with insulin
signaling in skeletal muscle cells.
Figure 5. Correlation of glucose uptake and insulin level with mean centroid expression levels of reporter metabolite neighbor
genes (Swedish male dataset). M value – whole-body glucose uptake during the hyperinsulinemic euglycemic clamp, Insulin 120 min – insulin
levels achieved at the two hour time point of oral glucose tolerance test.
doi:10.1371/journal.pcbi.1000729.g005
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Supplementary tables S1, S2, S3, S4 list additional reporter
metabolites which are, to our knowledge, not (directly) linked with
any of the known metabolic players in T2DM. Our analysis
nevertheless suggests them as potential nodes of disruption or as
biomarkers. Measurement of the intramyocellular concentration of
the reporter metabolites in patients with diabetes risk may help to
confirm the role of these metabolites in insulin resistance.
Metabolic hubs as reporters
A particularly interesting finding from our analysis is the
identification of highly connected metabolites as reporters,
including ATP/ADP and NAD+/NADH. We hypothesize that
diverse environmental and genetic risk factors result in insulin
resistance when individuals are unable to mediate appropriate
compensatory transcriptional and metabolic responses in other
parts of the network connected by these hubs. Our results also
suggest that alterations in gene expression linked to the highly
connected co-factors are likely to be acquired features of
established T2DM. Analysis of the transcriptional activity of
CREB in the context of ATP concentrations and TCA cycle
activity in skeletal muscle may help to elucidate regulatory
mechanisms leading to these changes.
Constraints and extension of methodology
Reconstructed human metabolic network models are still
evolving, incomplete, and subject to error. Well-annotated
pathways such as central carbon metabolism are thereby likely
to be over-represented in the reporter analysis. In order to partially
compensate for this limitation, we used two reconstructions –
Recon1 and EHMN. As network reconstructions will become
more complete, it will be possible to better assess the extent of this
limitation. Another essential input to our algorithm, in addition to
metabolic network, is gene expression data for the genes
represented in the network. We would like to note that neither
EHMN nor Recon1 network genes were fully represented by the
microarray chips used in the two case studies (Text S1). Only 54%
and 39% genes from the Recon1 and EHMN, respectively, were
represented on the chips used in Mexican-American case study,
while this coverage was 85% and 60% in Swedish case study.
Interestingly, re-analysis of the Swedish Male dataset by using only
a subset of genes from the HG-U133A chip that were represented
also on the HuGeneFL (used in Mexican-American case study)
showed a large overlap between the two reporter metabolite sets
thus obtained (86% for T2DM vs NGT comparison and 69% for
the rest). The details of this analysis, together with relevant
statistical considerations, can be found in Text S1.
Although the present analysis identified common metabolic and
regulatory signatures across the two studies, there are several
differences in the study designs, and therefore the results must be
regarded with certain caution. In addition to relatively low
number of subjects in Mexican-American study, the differences
include fasting state biopsies in Mexican-American study vs post
insulin stimulation biopsies in Swedish study. Furthermore, the age
and BMI (Body Mass Index) of the individuals participating in the
two studies were different and may contribute to the differences in
the observed gene expression patterns. To our knowledge, these
two case studies represent the only human skeletal muscle
transcriptome datasets that were available at the time of here
reported computational analysis. Analysis of new datasets which
may become available in the future will be useful in obtaining
further insight into molecular physiology of skeletal muscle in the
context of T2DM. Moreover, emergence of better or new gene
expression analysis tools will help to cover parts of metabolic
network that are currently inaccessible due to the lack of data.
Extension of the analysis to discover more global regulatory
patterns by using additional bio-molecular interaction data [58]
such as protein-DNA and protein-protein interactions will definitely
be an important step in obtaining a higher resolution picture of
T2DM metabolic phenotypes. Availability of such interaction data
at the high confidence level of metabolic interactions is the current
major bottleneck. Another essential extension of the methodology
will require the use of thermodynamic data for metabolic reactions
[59–61]. Moreover, since mRNA levels do not necessarily correlate
with the protein levels, incorporation of the proteomics data
together with the thermodynamic data will allow more accurate
interpretation of the reporter metabolites in terms of implications
for flux and concentration changes.
Conclusions
We demonstrate the use of a network-guided data integration
approach to discover key, physiologically relevant metabolic and
regulatory nodes in T2DM pathogenesis. The methodology does
not require the use of a priori disease-specific knowledge regarding
the involvement of specific pathways or metabolites, thereby making
it a robust and unbiased analytical framework for studying diseases
linked to perturbations in the cellular metabolic network. Our
results identify the highly connected metabolites ATP and NAD+ as
reporters and potential mediators of the widespread changes in gene
expression linked to insulin resistance in muscle. Moreover, our
results extend previous knowledge about T2DM pathogenesis at the
gene expression level – by reporting additional potential sites of
disruption, e.g., TCA cycle and Kennedy pathway of phospholipid
metabolism. Several metabolites from other pathways were also
found to display significant differential gene expression of the genes
around them and we suggest putative regulatory mechanisms
behind these alterations. Our results suggest a framework of
metabolic disruption observed with insulin resistance and diabetes,
which can be used to test the role of specific pathways in mediating
disease pathophysiology, and more practically, for the identification
of potential biomarkers for preventive and therapeutic monitoring.
Materials and Methods
Gene expression and sequence data
Two datasets used in the study were obtained from the Diabetes
Genome Anatomy Project website (http://www.diabetesgenome.
org). Brief comparison of microarray platforms from the
experimental studies [8,9] used in the current work is presented
in the Text S1. Promoter sequences for all genes were obtained
from the Ensembl Biomart (http://www.ensembl.org/biomart).
The transcriptional start sites (TSSs) were identified based on the
annotation of the Ensembl Biomart sequences. Sequences in the
2800 to 200 base pairs region of the TSS were deemed as
promoter regions for the analysis. Interspersed repeats and low
complexity DNA sequences were masked out.
Metabolic networks
Two reconstructions of human metabolic network, viz., Recon1
[19] and EHMN [62] were used in this study. The Homo Sapiens
Recon1 is a comprehensive literature-based metabolic network
reconstruction that accounts for the functions of 1496 ORFs, 2004
proteins, 2766 metabolites and 3311 metabolic and transport
reactions. The ENMN (Edinburgh Human Metabolic Model) is a
network reconstructed by integrating genome annotation information
from different databases and metabolic reaction information from the
literature. The network contains nearly 3000 metabolic reactions,
which were reorganized into about 70 human-specific pathways
according to their functional relationships. The two models mainly
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differ in the coverage of reactions and in the accounting of
compartmentalization and inter-organelle transport reactions.
Significance of differential gene expression
Preprocessing of the gene expression data was carried out by using
the statistical software environment – R (www.r-project.org). The
probe intensities were obtained and corrected for background by
using robust multi-array average method (RMA) [63] with only
perfect-match (PM) probes. Normalization was performed by using
the quantiles algorithm. Gene expression values were calculated from
the PM probes with the median polish summarization method [63].
All data preprocessing methods were used by invoking them through
the affy package [64] by using rma function. Significance of the
differential expression was calculated by using the empirical Bayes
test [65]. The probe-sets were grouped into genes, and to each gene
the differential expression was defined by choosing the value from the
top level probe-set (using the probe-set rank defined by Affymetrix).
In case of more than one probe-set present at the top level, the
median value was used.
Reporter metabolites
Each metabolite in the metabolic network was scored based on
the scores of its k neighbor enzymes (i.e. enzymes catalyzing
reactions involving that metabolite, either as a substrate or as a
product). Each enzyme was assigned with a p-value for differential
expression based on the p-value of the gene encoding for that
enzyme. In case of isozymes and enzyme-complexes, genes with
most significant expression change were used to score the enzyme
(Figure 1). P-values of genes pi, indicating the significance of
differential expression, were converted to Z-scores Zi by using the
inverse normal cumulative distribution function (CDF) (h{1):
Zi~ h
{1 1{pið Þ. All metabolite nodes were assigned a Z-score,
Zmetabolite, calculated as aggregated Z scores of the k neighbor
enzymes:Zmetabolite~
1
k
X
Zni. Zmetabolite scores were then corrected
for the background distribution by subtracting the mean (mk) and
dividing by the standard deviation (sk) of the aggregated Z scores
derived by sampling 10000 sets of k enzymes from the network:
Zcorrectedmetabolite~
Zmetabolite{mkð Þ
sk
. Corrected Z-scores were then trans-
formed to p-values by using CDF. Metabolites with p-values less
than 0.05 were deemed as reporter metabolites. Detailed informa-
tion on the reporter scoring can be found in the Text S1 and [14].
Transcription factor binding site enrichment
For all reporter metabolites, we assessed enrichment of known
protein-binding sequence motifs in the promoter regions (2800 to
200 base pairs relative to the transcription start site) of the
corresponding neighbor genes. In order to obtain robust results,
we only considered sets consisting of at least 5 up- or down-
regulated genes. For each reporter metabolite, the sequences of all
enzyme neighbors were used as the positive sequence set, whereas
all other enzymes in the network model were used as the negative
(background) set. Known motifs were identified by using position
frequency matrices of all known motifs stored in the TRANSFAC
database [66]. The motif enrichment analysis tool ASAP [67] was
used to scan all TRANSFAC motif matrices against the positive
sequence sets of each reporter metabolite. The negative sequence
sets were used together with 2nd order background model. A one-
tailed Fisher’s exact test was used to assess per-sequence over-
representation of any known motif, and the threshold used to
calculate significance for each TRANSFAC matrix was set to 70%
of the highest-scoring sequence motif. The q-value cut-off criteria
[29] was used as a post-data measure of statistical significance of all
motifs found to be significantly enriched.
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